BR112013009984A2 - anticorpos para tratamento do hiv - Google Patents

anticorpos para tratamento do hiv

Info

Publication number
BR112013009984A2
BR112013009984A2 BR112013009984A BR112013009984A BR112013009984A2 BR 112013009984 A2 BR112013009984 A2 BR 112013009984A2 BR 112013009984 A BR112013009984 A BR 112013009984A BR 112013009984 A BR112013009984 A BR 112013009984A BR 112013009984 A2 BR112013009984 A2 BR 112013009984A2
Authority
BR
Brazil
Prior art keywords
antibodies
cxcr4
hiv
relates
present
Prior art date
Application number
BR112013009984A
Other languages
English (en)
Inventor
Klinguer-Hamour Christine
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41060014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013009984(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Priority claimed from PCT/EP2011/068905 external-priority patent/WO2012055980A1/en
Publication of BR112013009984A2 publication Critical patent/BR112013009984A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos para tratamento do hiv. a presente invenção refere-se aos anticorpos isolados, ou os seus derivados ou fragmentos de antigenio de ligação do mesmo, capazes de se ligarem ao cxcr4, mas também a indução da mudança conformacional dos homodímeros cxcr4 e capazes de inibir a replicação do hiv-1 em pbmc isolado primário. mais particularmente, a presente invenção relaciona-se com anticorpos monoclonais 515h7 e 301 ae5, específicos para a proteína do receptor cxcr4, bem como a sua utilização para o tratamento da infecção por hiv. as composições farmacêuticas que compreendem estes anticorpos e um processo para a seleção de tais anticorpos, também são abrangidas.
BR112013009984A 2009-04-29 2011-10-27 anticorpos para tratamento do hiv BR112013009984A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09159076A EP2246364A1 (en) 2009-04-29 2009-04-29 Anti CXCR4 antibodies for the treatment of HIV
US12/913,300 US9090686B2 (en) 2009-04-29 2010-10-27 Antibodies for the treatment of HIV
PCT/EP2011/068905 WO2012055980A1 (en) 2010-10-27 2011-10-27 Antibodies for the treatment of hiv

Publications (1)

Publication Number Publication Date
BR112013009984A2 true BR112013009984A2 (pt) 2017-07-18

Family

ID=41060014

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1011540-4A BRPI1011540A2 (pt) 2009-04-29 2010-04-29 anticorpos anticxcr4 para o tratamento de of hiv
BR112013009984A BR112013009984A2 (pt) 2009-04-29 2011-10-27 anticorpos para tratamento do hiv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI1011540-4A BRPI1011540A2 (pt) 2009-04-29 2010-04-29 anticorpos anticxcr4 para o tratamento de of hiv

Country Status (26)

Country Link
US (3) US9090686B2 (pt)
EP (2) EP2246364A1 (pt)
JP (1) JP5800802B2 (pt)
KR (1) KR20120039525A (pt)
CN (1) CN102459343B (pt)
AU (1) AU2010243526B2 (pt)
BR (2) BRPI1011540A2 (pt)
CA (1) CA2759989A1 (pt)
CL (1) CL2011002664A1 (pt)
CO (1) CO6390114A2 (pt)
ES (1) ES2534313T3 (pt)
GE (1) GEP20146181B (pt)
HK (1) HK1165813A1 (pt)
HU (1) HUE025083T2 (pt)
IL (1) IL215919A0 (pt)
MA (1) MA33285B1 (pt)
MX (1) MX2011011285A (pt)
MY (1) MY155400A (pt)
NZ (1) NZ596712A (pt)
PL (1) PL2424897T3 (pt)
RU (1) RU2573902C2 (pt)
SG (1) SG175353A1 (pt)
TN (1) TN2011000534A1 (pt)
UA (1) UA107929C2 (pt)
WO (1) WO2010125162A1 (pt)
ZA (1) ZA201108330B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
AU2011322508A1 (en) * 2010-10-27 2013-05-02 Pierre Fabre Medicament Antibodies for the treatment of HIV
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
US9587012B2 (en) 2013-12-02 2017-03-07 Aaron Diamond Aids Research Center Bispecific HIV-1 neutralizing antibodies
NZ743713A (en) 2015-12-15 2020-01-31 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
US11180575B2 (en) 2018-12-28 2021-11-23 Corn Products Development, Inc. Thermally inhibited starch and process for making
CN111918873A (zh) 2018-03-27 2020-11-10 百时美施贵宝公司 使用紫外线信号实时监测滴度
CN111214650A (zh) * 2018-11-23 2020-06-02 广州溯原生物科技有限公司 一种hiv抗原-受体三聚体复合物的解离因子的应用
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
CA3167936A1 (en) * 2020-01-16 2021-07-22 Cohava Gelber Humanized antibodies specific for myeloma and ovarian cancer cells
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
US12006353B2 (en) * 2022-07-25 2024-06-11 Long Chen Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5871732A (en) * 1990-11-27 1999-02-16 Biogen, Inc. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69334287D1 (de) * 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
EP0854918A1 (en) * 1996-01-30 1998-07-29 The National Institutes of Health Cells expressing both human cd4 and cxcr4
WO2001042308A2 (en) * 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
MXPA06000252A (es) * 2003-06-30 2006-12-15 Bio Technology General Israel Anticuerpos y usos de los mismos.
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
KR20090052358A (ko) * 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
JP5374360B2 (ja) * 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
JP2011520885A (ja) * 2008-05-14 2011-07-21 イーライ リリー アンド カンパニー 抗ｃｘｃｒ４抗体
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
WO2011059684A1 (en) * 2009-10-29 2011-05-19 Centocor Ortho Biotech Inc. Antibody glycosylation variants
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
CL2011002664A1 (es) 2012-12-14
MX2011011285A (es) 2012-01-20
PL2424897T3 (pl) 2015-07-31
KR20120039525A (ko) 2012-04-25
EP2246364A1 (en) 2010-11-03
UA107929C2 (en) 2015-03-10
RU2011148077A (ru) 2013-06-10
ZA201108330B (en) 2012-09-26
US20160031995A1 (en) 2016-02-04
BRPI1011540A2 (pt) 2019-04-30
JP2012525129A (ja) 2012-10-22
MY155400A (en) 2015-10-15
IL215919A0 (en) 2011-12-29
CO6390114A2 (es) 2012-02-29
ES2534313T3 (es) 2015-04-21
CA2759989A1 (en) 2010-11-04
AU2010243526B2 (en) 2015-02-12
WO2010125162A1 (en) 2010-11-04
HK1165813A1 (en) 2012-10-12
JP5800802B2 (ja) 2015-10-28
AU2010243526A1 (en) 2011-12-22
US20130174288A1 (en) 2013-07-04
SG175353A1 (en) 2011-11-28
US20110088104A1 (en) 2011-04-14
MA33285B1 (fr) 2012-05-02
CN102459343B (zh) 2015-09-16
TN2011000534A1 (en) 2013-05-24
NZ596712A (en) 2013-10-25
GEP20146181B (en) 2014-10-27
RU2573902C2 (ru) 2016-01-27
EP2424897B1 (en) 2015-01-07
HUE025083T2 (en) 2016-02-29
EP2424897A1 (en) 2012-03-07
US9090686B2 (en) 2015-07-28
CN102459343A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
BR112013009984A2 (pt) anticorpos para tratamento do hiv
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
BR112013004056B8 (pt) Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
BR112012024710A8 (pt) moléculas que se ligam ao antígeno, seus processos de produção, bem como composição farmacêutica que as compreendem
BR112012010270A2 (pt) mentisulfonilmetano (msm) para tratamento de micro-organismos resistentes a fármaco
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
BRPI0717156B8 (pt) inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BRPI1008145B8 (pt) Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112016022553A2 (pt) Compostos e métodos para entrega transmembrana de moléculas?
AR075989A1 (es) Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
BR112016023979A2 (pt) métodos de melhora ou aceleração da recuperação física após cirurgia para fratura óssea
BR112012009376B8 (pt) composição farmacêutica sólida compreendendo um inibidor de sglt-2 e sua forma de dosagem farmacêutica
BRPI0713443A2 (pt) Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos
BR112013007314A2 (pt) anticorpos anti-cd48 e seus usos
BR112012008282A2 (pt) anticorpos de neutralização anti-nfg humanos como inibidores de curso de ngf seletivos
BR112022003589A2 (pt) Conjugado de anticorpo-fármaco compreendendo anticorpo contra ror1 humano e uso para o mesmo
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
BRPI0817242A8 (pt) compostos derivados de 1,1,1-trifluoro-2-hidroxi-3-fenilpropano, processo para a sua manufatura e composições farmacêuticas que os contêm
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BR112012009432A2 (pt) anticorpo anti-hsv
BR112018007318A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, e, métodos para tratar uma doença ou condição.
BR112012022258A2 (pt) anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]